^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

U3-1784

i
Associations
Trials
Company:
Daiichi Sankyo
Drug class:
FGFR4 inhibitor
Associations
Trials
over4years
Pre-clinical development of U3-1784, a novel FGFR4 antibody against cancer, and avoidance of its on-target toxicity. (PubMed, Mol Cancer Ther)
The FGFR4/FGF19 signaling axis is overactivated in 20% of liver tumors and currently represents a promising targetable signaling mechanism in this cancer type. These effects could be completely prevented by the concomitant oral treatment with the bile acid sequestrant colestyramine, which binds and eliminates bile acids in the gut. These results offer a new biomarker-driven treatment modality in liver cancer without toxicity and they suggest a general strategy for avoiding adverse events with FGFR4 inhibitors.
Preclinical • Journal
|
FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • FRS2 (Fibroblast Growth Factor Receptor Substrate 2)
|
U3-1784